Der Thementhread zu BioVaxys Technology
Seite 14 von 125 Neuester Beitrag: 15.05.23 20:00 | ||||
Eröffnet am: | 18.03.21 11:45 | von: The Sailor | Anzahl Beiträge: | 4.106 |
Neuester Beitrag: | 15.05.23 20:00 | von: Lalle1895 | Leser gesamt: | 844.113 |
Forum: | Hot-Stocks | Leser heute: | 32 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 11 | 12 | 13 | | 15 | 16 | 17 | ... 125 > |
Zur Info für alle. Die LunaPR-Dame hat gestern bzgl. einer anstehenden "exciting campaign" folgendes angekündigt:
"About 2 weeks for the campaign to launch and should start seeing positive traction after 3-4 weeks :)"
Posts, die aus 2 Wörtern mit insgesamt 5 Buchstaben bestehen und sich stark nach einem Teenager anhören, halte ich wiederum für ziemlich belanglos.
We have high hopes for our haptenized antigen technology in the field of Adoptive Immunotherapy which is when T-cells are collected from a patient and grown in the laboratory. This increases the number of T-cells that are able to kill cancer cells such as HPV, cervical cancer and ovarian cancer. In recent finding T-cells have also been shown to be effective against fighting SARS-CoV-2.
Learn more at biovaxys.com
#tcells #covid #vaccine #anticancer #immunotherapy
Wenn das aufgeht, knallts.
>>announced today that it has filed with the United States Patent & Trademark Office ("USPTO") an intent-to-use application to register the mark CoviDTH®, it's novel disposable T-cell immune response diagnostic for SARS-CoV-2.
BioVaxys President and CEO Kenneth Kovan commented "As we get closer to market, we needed to register a trademark that would be descriptive, memorable, and defendable. CoviDTH® is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19."<<
Natürlich bringe ich mich auch mit Links weiter ein ;-)